Columns
- All
- Advanced Degrees
- Analyze This
- Back Page
- Clinically Speaking
- Data Integrity
- Deal Discussions
- Editorial
- Emerging Markets
- Executive Perspective
- FDA Watch
- Financial Analysis
- Getting Results
- I Mak
- India Report
- Lowe Down
- Managing Your Career
- Newsmakers Interviews
- Opinions & Best Practices
- PBOA News
- Pharma Beat
- Preclinical Outsourcing
- The BioPharm Insider
-
Antimicrobial Resistance ‘Arms Race’ Realizes Advancements as Post-Antibiotic Era Ensues
Emerging innovations and non-antibiotic approaches to address urgent need to control infectious diseases, including multiple-drug resistant ‘super-bugs’.Merilee Kern, MBA, Brand Analyst, Strategist and Futurist, and Forbes Business Council Member 09.09.21
-
Clinical Trials
The Future of Clinical Trials
Dr. Greg Licholai of ICON plc on key market trends, the future of clinical trials and the acquisition of PRA.Kristin Brooks, Managing Editor 09.09.21
-
-
Planning For Better Clinical Trials
Faster, smoother and more approvable clinical trials start with you.Ben Locwin, Contributing Editor 09.09.21
-
Let’s Get Genuine
LinkedIn sales pitches are going away in favor of being real.David G. Jensen, Contributing Editor 09.09.21
-
-
Waking from the “Coma of COVID-19”
What should the “New Normal” look like?Emil W. Ciurczak, DoraMaxx Consulting 06.07.21
-
Information Technology | QA/QC | Regulatory Affairs
The Importance of Data Integrity Risk Assessment
Executing Data Integrity Risk Assessments for systems that generate and store both paper (manual)-based systems as well as computer-based and hybrid systems.Paul Mason, Ph.D., Lachman Consultants 06.07.21
-
Motivating Your Scientists and Engineers
It’s more than just money or stock.David G. Jensen, Contributing Editor 06.07.21
-
Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines
The Future of Continuous Bioprocessing
The modernization of advanced therapy manufacturing.Dr. Karoline Hahn, Senior Consultant for Advanced Therapies, KCR 06.02.21
-
The Word ‘Innovation’ Probably Doesn’t Mean What You Think It Does
Innovation in manufacturing can come in many forms.Ben Locwin, Contributing Editor, International COVID-19 Advisor, Healthcare Futurist 05.05.21
-
Analytical Services
Too Much of a Good Thing?
Watch out for that pendulum!Emil W. Ciurczak, DoraMaxx Consulting 05.05.21
-
The Changing Nature of Communications
Is Zoom burnout leading to a resurgence of the “good-ol” phone call?David G. Jensen, Contributing Editor 05.05.21
-
Ensuring Pharma Manufacturing Quality
How today’s life sciences manufacturers can effectively monitor processes, integrate with sub-contractors and align with regulatory reporting requirements.Shahid Manzur, Principal, EY Consulting 05.05.21
-
Biologics, Proteins, Vaccines | Regulatory Affairs
What Will Change at FDA for 2021?
(R)evolution of the industry’s data, catalyzed by changes at FDA and what’s the likely impact to the pharmaceutical industry?Ben Locwin, Contributing Editor, International COVID-19 Advisor, Healthcare Futurist 04.01.21
-
Drug Delivery
The Ever-Evolving World of Combination Products
Looking at the benefits and challenges of the trend towards combination products.Ricki A. Chase, M.S, Lachman Consultants 04.01.21
-
Professional Etiquette at Two Critical Moments
Starting, or leaving, a job presents unique challenges.David G. Jensen, Contributing Editor 04.01.21
-
Regulatory Affairs
Post-Pandemic Regulations
Envisioning clinical development regulatory practices in a post-pandemic world.Ronan Brown, SVP and Head of Integrated Global Compliance, IQVIA 04.01.21
-
Information Technology
Life Sciences Strive for Greater Agility
Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.Ronan Brown and Joe Rymsza, IQVIA 03.01.21
-
Biologics, Proteins, Vaccines
Vaccines and Return-To-Normalcy
Planning for a future in which COVID-19 won’t simply ‘disappear.’Ben Locwin, Contributing Editor 03.01.21
